Can we use pre-therapy PSMA PET/CT as a predictor for Lutetium-177-PSMA-617 therapy? Early experience from the Canadian Cancer Trials Group PR21 trial (NCT 04663997)

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

You are going to email the following Can we use pre-therapy PSMA PET/CT as a predictor for Lutetium-177-PSMA-617 therapy? Early experience from the Canadian Cancer Trials Group PR21 trial (NCT 04663997)

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.